Logo

AbbVie's Rinvoq (upadacitinib) Receives EC's Approval for the Treatment of Moderate to Severe Atopic Dermatitis

Share this
AbbVie's Rinvoq (upadacitinib) Receives EC's Approval for the Treatment of Moderate to Severe Atopic Dermatitis

AbbVie's Rinvoq (upadacitinib) Receives EC's Approval for the Treatment of Moderate to Severe Atopic Dermatitis

Shots:

  • The approval is based on 3 P-III studies i.e.- Measure Up 1/2/AD Up evaluating the efficacy & safety of Rinvoq (15/30 mg- qd) as monothx. with TCS vs PBO in 2500+ adults & adolescents with AD
  • The studies met its 1EPs & 2EPs @16wks. i.e.- improvement in skin clearance & itch reduction- patients achieved EASI 75 (70%/ 60%/65%) & (80%/ 73%/ 77%) vs (16%/13%/26%); vIGA-AD 0/1 (48%/39%/31%) & (62%/ 52%/ 59%) vs (8%/5%/11%)- improvement in Worst Pruritus NRS ≥4 (52%/ 42%/ 52%) & (60%/ 60%/ 64%) vs (12%/ 9%/ 15%). The results continued to be maintained for 52wks.
  • The approval marks the 4th indication in the EU with previous approval in RA- PsA & AS and is approved in the US for RA

Click here  | Ref: Abbvie | Image:abbvie

Click here to­ read the full press release 

Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions